Biohaven EBIT per Share
The EBIT per Share of Biohaven (BHVN) as of Nov 13, 2026 is -6.20 USD. In the previous year, EBIT per Share was -8.76 USD — a change of -29.19% (higher).
Get this data via API
Financial Data API
EBIT per Share
-6.20USD
YoY
-29.19%
Last updated:
EBIT per Share of Biohaven is 2025 -6.20 USD. EBIT per Share of Biohaven was 2024 -8.76 USD. It decreases by -29.19% higher compared to the previous year.
The Biohaven EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-5.46 USD
Jan 1, 2024
-8.76 USD
Jan 1, 2025
-6.20 USD
Jan 1, 2026 (e)
-3.87 USD
Jan 1, 2027 (e)
-3.31 USD
Jan 1, 2028 (e)
-2.58 USD
Jan 1, 2029 (e)
-1.50 USD
Jan 1, 2030 (e)
1.85 USD
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 1.85USD | -223.56% |
| est | -1.50USD | -41.87% |
| est | -2.58USD | -22.15% |
| est | -3.31USD | -14.45% |
| est | -3.87USD | -37.58% |
| -6.20USD | -29.19% | |
| -8.76USD | +60.55% | |
| -5.46USD | -41.54% | |
| -9.33USD | +67.82% | |
| -5.56USD | +135.46% | |
| -2.36USD | -74.15% | |
| -9.13USD | +59.42% | |
| -5.73USD | +129.93% | |
| -2.49USD | +525.05% | |
| -0.40USD | +555.41% | |
| -0.06USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Biohaven Stock analysis
What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Biohaven stock
EBIT per Share of Biohaven is -6.20 USD in 2025.
EBIT per Share of Biohaven changed from -8.76 USD to -6.20 USD, representing a -29.19% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Biohaven since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Biohaven
All Key Metrics — Biohaven
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth